Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Director · President and CEO | March 14, 2019 | March 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Insight Molecular Diagnostics Inc.
Report date March 14, 2019 · Filed March 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.52 · Expires 2029-03-13 | Direct | 390,000 |
Reported balance
After 2019-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-14 · Grant · Acquired 390,000 · Balance 390,000 F1: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on March 14, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on March 14, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2019 Filed Mar 19, 2019 00:06 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 390,000 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001209191-19-020142 · doc4.xml · derivative · entry 1 ANNETT WILLIAM · CIK 0001662553 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2029-03-13 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on March 14, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date. Read SEC document |
| July 26, 2018 Filed Aug 1, 2018 01:40 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock purchase warrants · Derivative | 3,500 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001493152-18-010766 · ownership.xml · derivative · entry 2 ANNETT WILLIAM · CIK 0001662553 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common stock · 3,500 shares Expires 2024-02-01 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| July 26, 2018 Filed Aug 1, 2018 01:40 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock, no par value | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-010766 · ownership.xml · nonDerivative · entry 1 ANNETT WILLIAM · CIK 0001662553 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| May 23, 2018 Filed Jun 1, 2018 23:41 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 180,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-18-034866 · doc4.xml · derivative · entry 1 ANNETT WILLIAM · CIK 0001662553 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: One quarter of the options shall vest upon completion of the clinical utility study for OncoCyte's DetermaVu product candidate and OncoCyte has received a publication date for a full article describing those results, and the balance shall vest upon obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate. Read SEC document |
| February 17, 2017 Filed Feb 23, 2017 02:09 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 225,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-17-013557 · doc4.xml · derivative · entry 1 ANNETT WILLIAM · CIK 0001662553 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 225,000 shares Expires 2027-02-16 F1 · derivative.exercise_date: One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.